Skin diseases associated with atopic dermatitis

Fenner, Justine; Silverberg, Nanette B.

doi:10.1016/j.clindermatol.2018.05.004

Cited by 55 publications

(63 citation statements)

References 117 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have described M. sympodialis as the most abundant in patients with atopic dermatitis and the possibility of its coexistence with a non-Malassezia species called Cryptococcus diffluens (17). In addition, many patients with AD have associated IgE mediated sensitization to Malassezia species, with positive skin prick tests (18,19). The rate of IgE mediated Malassezia sensitization correlates with disease severity (18,20).…”

Section: Modulating the Human Microbiome By Pre-and Probioticsmentioning

confidence: 99%

See 1 more Smart Citation

Prebiotics and probiotics in atopic dermatitis (Review)

et al. 2019

View full text Add to dashboard Cite

Recent years have brought additional data on the benefits of prebiotics and probiotics treatment in patients with atopic dermatitis. This review includes all the articles published in PubMed, Scopus, Embase and Cochrane databases until 05.06.2018. The terms used for the search were 'prebiotic', 'probiotic', 'atopic dermatitis', 'Severity Scoring of Atopic Dermatitis', and 'SCORAD'. There was an increase of the intestinal permeability reported in patients with atopic dermatitis and a reduction of the cutaneous microbiome diversity. Probiotics modulate the general microbiome and immune status by improving the intestinal barrier; these effects can be responsible for reducing allergic phenomenon and atopic dermatitis severity. We have structured the results by age groups as infants, 1-18 years, adults, and also pregnancy and lactation. Literature does not offer yet answers on the issues such as the optimal dosing, duration needed to see beneficial effects, the optimal time to start the treatment; the personalized use of probiotics according to colonic dysbiosis may be associated with better results. However, most randomized controlled trials and meta-analyzes support the administration of probiotics for at least 8 weeks in order to obtain beneficial effects in improving severity scoring of atopic dermatitis. Contents 1. Introduction 2. Definition of terms 3. Modulating the human microbiome by pre-and probiotics 4. Prebiotic and probiotic in atopic dermatitis 5. The type of probiotics used in clinical trials 6. Prebiotics-mechanism of action 7. Probiotics-mechanism of action 8. Conclusion

show abstract

Section: Modulating the Human Microbiome By Pre-and Probioticsmentioning

confidence: 99%

“…In addition, many patients with AD have associated IgE mediated sensitization to Malassezia species, with positive skin prick tests (18,19). The rate of IgE mediated Malassezia sensitization correlates with disease severity (18,20).…”

Section: Modulating the Human Microbiome By Pre-and Probioticsmentioning

confidence: 99%

Prebiotics and probiotics in atopic dermatitis (Review)

et al. 2019

View full text Add to dashboard Cite

show abstract

“…U pacjentów z AZS często występuje łupież biały (pityriasis alba) i rogowacenie mieszkowe (keratosis pilaris). Defekt filagryny predysponuje do lepszej penetracji haptenów chemicznych i rozwoju alergicznego wyprysku kontaktowego (ACD) [8,9]. Przewlekły stres i bezsenność wiążą się z trudnościami w nauce i pracy.…”

Section: Zakład I Klinika Dermatologii Uniwersytet Rzeszowskiunclassified

“…Opisano związek AZS z chorobami zapalnymi jelit, układowym toczniem rumieniowatym, otyłością, zespołem metabolicznym, cukrzycą, nadciśnieniem tętniczym, chorobami sercowo-naczyniowymi, udarami, osteoporozą i wtórnymi złamaniami. Ciężkie i przewlekłe AZS może być związane w życiu dorosłym z chłoniakiem skóry [6,8,[11][12][13][14]. Sprzeczne są wyniki badań nad związkiem Dermatology Review/Przegląd Dermatologiczny 2018/6 AZS z cukrzycą typu 1, autoimmunologicznym zapaleniem tarczycy i reumatoidalnym zapaleniem stawów (RZS) [13].…”

Section: Zakład I Klinika Dermatologii Uniwersytet Rzeszowskiunclassified

VI Konferencja Kontrowersje w Dermatologii Streszczenia

2018

View full text Add to dashboard Cite

“…e pathogenesis of AD is multifactorial, including genetic, and environmental factors. Also, AD is characterized by skin barrier defects, immunologic dysfunction, and alterations in the skin microbiome [7][8][9]. However, a number of cytokines and mediators involved in 2, 22, 17, and 1 pathways appear to be important in AD pathogenesis, and there is currently an increasing interest in developing targeted therapies, especially for patients with moderate-to-severe forms of the disease not responding to conventional treatments [10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Consensus on the Clinical Approach to Moderate-to-Severe Atopic Dermatitis in Spain: A Delphi Survey

Sastre

Baldrich

Hita

et al. 2020

Dermatology Research and Practice

View full text Add to dashboard Cite

Background. The purpose of this study was to gather information on the current assessment and management of patients with moderate-to-severe AD in routine daily practice. Methods. A cross-sectional two-round Delphi survey with the participation of dermatologists and allergologists throughout Spain was conducted. They completed a 46-item questionnaire, and consensus was defined when responses of ≥80% of participants coincided in the categories of a 5-point Likert scale for that item. Results. A total of 105 specialists (aged 40–59 years) completed the two rounds. Participants agreed regarding the consideration of AD as a multifaceted disease and the differences in clinical presentation of AD according to the patient’s age. It is recommendable to perform a skin biopsy to exclude early stage T-cell cutaneous lymphoma, psoriasis, or dermatitis herpetiformis, among others (99.1%). Also, consensus was reached regarding the use of the SCORAD index to quantify the severity of the disease (86.7%), the use of wet wraps to increase the effect of topical corticosteroids (90.4%), the usefulness of proactive treatment during follow-up (85.6%) and tacrolimus ointment (91.2%) to reduce new flares, and the fact that crisaborole is not the treatment of choice for severe AD (92.4%). AD was not considered a contraindication for immunotherapy in patients with allergic respiratory diseases (92.4%). In patients with severe AD, the use of immune response modifier drugs (97.6%) or phototherapy (92.8%) does not sufficiently cover their treatment needs. Consensus was also obtained regarding the role of the new biologic drugs (93.6%) targeting cytokines involved in the Th2 inflammatory pathway (92.0%) and the potential role of dupilumab as first-line treatment (90.4%) in moderate-to-severe AD patients. Conclusion. This study contributes a reference framework to the care of AD patients. There is no diagnostic test or biomarkers to direct treatment or to assess the severity of the disease, and many therapeutic challenges remain.

show abstract

Skin diseases associated with atopic dermatitis

Cited by 55 publications

References 117 publications

Prebiotics and probiotics in atopic dermatitis (Review)

Prebiotics and probiotics in atopic dermatitis (Review)

VI Konferencja Kontrowersje w Dermatologii Streszczenia

Consensus on the Clinical Approach to Moderate-to-Severe Atopic Dermatitis in Spain: A Delphi Survey

Contact Info

Product

Resources

About